CN118234497A - 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) - Google Patents
通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) Download PDFInfo
- Publication number
- CN118234497A CN118234497A CN202280073517.6A CN202280073517A CN118234497A CN 118234497 A CN118234497 A CN 118234497A CN 202280073517 A CN202280073517 A CN 202280073517A CN 118234497 A CN118234497 A CN 118234497A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- menin
- gist
- moz
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289943P | 2021-12-15 | 2021-12-15 | |
| US63/289,943 | 2021-12-15 | ||
| PCT/US2022/081587 WO2023114867A2 (en) | 2021-12-15 | 2022-12-14 | Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118234497A true CN118234497A (zh) | 2024-06-21 |
Family
ID=86773651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280073517.6A Pending CN118234497A (zh) | 2021-12-15 | 2022-12-14 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041299A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4447972A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025503385A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240121720A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118234497A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022410890A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3235383A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL311862A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024007201A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023114867A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| US12187732B2 (en) | 2022-03-28 | 2025-01-07 | Isosterix, Inc. | Inhibitors of the myst family of lysine acetyl transferases |
| AR132185A1 (es) | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| JP2026525148A (ja) * | 2023-07-17 | 2026-07-29 | クラ オンコロジー，インク． | メニン阻害剤を含む医薬組成物 |
| IL325861A (en) | 2023-07-17 | 2026-03-01 | Kura Oncology Inc | Crystalline forms of a menin inhibitor |
| KR20260099138A (ko) * | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| IL328224A (en) * | 2023-11-17 | 2026-07-01 | Kura Oncology Inc | Methods for treating KIT-positive cancer with a menin inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016197027A1 (en) * | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| US10752639B2 (en) * | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
-
2022
- 2022-12-14 MX MX2024007201A patent/MX2024007201A/es unknown
- 2022-12-14 CN CN202280073517.6A patent/CN118234497A/zh active Pending
- 2022-12-14 CA CA3235383A patent/CA3235383A1/en active Pending
- 2022-12-14 IL IL311862A patent/IL311862A/en unknown
- 2022-12-14 US US18/717,194 patent/US20250041299A1/en active Pending
- 2022-12-14 WO PCT/US2022/081587 patent/WO2023114867A2/en not_active Ceased
- 2022-12-14 KR KR1020247016183A patent/KR20240121720A/ko active Pending
- 2022-12-14 AU AU2022410890A patent/AU2022410890A1/en active Pending
- 2022-12-14 JP JP2024533005A patent/JP2025503385A/ja active Pending
- 2022-12-14 EP EP22908673.1A patent/EP4447972A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311862A (en) | 2024-06-01 |
| WO2023114867A2 (en) | 2023-06-22 |
| KR20240121720A (ko) | 2024-08-09 |
| US20250041299A1 (en) | 2025-02-06 |
| EP4447972A2 (en) | 2024-10-23 |
| EP4447972A4 (en) | 2025-12-31 |
| WO2023114867A3 (en) | 2023-07-27 |
| MX2024007201A (es) | 2024-08-06 |
| CA3235383A1 (en) | 2023-06-22 |
| AU2022410890A1 (en) | 2024-05-02 |
| JP2025503385A (ja) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250041299A1 (en) | Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex | |
| Pan et al. | The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma | |
| US20240118266A1 (en) | Cell death biomarker | |
| US20170321281A1 (en) | Methods and compositions for treatment of glioblastoma | |
| Martínez-Martín et al. | MYC inhibitors in multiple myeloma | |
| US20220118070A1 (en) | Cancer therapy by modifying neoantigen expression | |
| Chen et al. | Downregulation of hsa_circ_0007580 inhibits non-small cell lung cancer tumorigenesis by reducing miR-545-3p sponging | |
| US20230158034A1 (en) | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors | |
| WO2022018667A1 (en) | Combination therapies using cdk2 and cdc25a inhibitors | |
| Graziano et al. | Mechanisms of oncogene-induced genomic instability | |
| Rahman et al. | CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer | |
| US20220288067A1 (en) | Treatment of cancer with cdk inhibitors | |
| US12024707B2 (en) | Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression | |
| Peng et al. | Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer | |
| Angel et al. | A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers | |
| Li et al. | NUP98‐p65 complex regulates DNA repair to maintain glioblastoma stem cells | |
| WO2021176008A1 (en) | Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer | |
| US20250146080A1 (en) | Methods for overcoming tazemetostat-resistance in cancer patients | |
| Matkar et al. | Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma | |
| CN113967261B (zh) | Folr1抑制剂的应用和治疗肝癌药物混合物 | |
| WO2019032810A2 (en) | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BETA-INHIBITORY RESISTANT CANCERS | |
| WO2021025018A1 (ja) | 大腸がんを治療及び／又は予防する医薬組成物 | |
| US20240398814A1 (en) | Kras inhibitor and hdac inhibitor combination for the treatment of cancer | |
| Vella | Identification of kinases implicated in temozolomide resistance in glioblastoma | |
| Sharma et al. | Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |